{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:31:13Z","timestamp":1759883473173,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.humpath.2025.105911","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T06:29:48Z","timestamp":1755930588000},"page":"105911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A real-world study on the expression and clinical application of IMP3 immunohistochemistry in bone tumors"],"prefix":"10.1016","volume":"164","author":[{"given":"Qingzhu","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"WHO classification of tumours soft tissue and bone tumours","key":"10.1016\/j.humpath.2025.105911_bib1"},{"issue":"1","key":"10.1016\/j.humpath.2025.105911_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jos.2023.11.007","article-title":"Japanese orthopaedic association (JOA) clinical practice guideline on the management of primary malignant bone tumors - secondary publication","volume":"30","author":"Tsuchiya","year":"2025","journal-title":"J Orthop Sci"},{"issue":"22","key":"10.1016\/j.humpath.2025.105911_bib3","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra2103423","article-title":"New Horizons in the treatment of osteosarcoma","volume":"385","author":"Meltzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.humpath.2025.105911_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41416-024-02868-4","article-title":"UK guidelines for the management of bone sarcomas","volume":"132","author":"Gerrand","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2025.105911_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fcell.2019.00363","article-title":"IMP3 from physiology to cancer: novel discoveries, unsolved issues, and future perspectives","volume":"7","author":"Mancarella","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"10.1016\/j.humpath.2025.105911_bib6","doi-asserted-by":"crossref","first-page":"9423","DOI":"10.3390\/ijms24119423","article-title":"Targeting IMP3 in cancer","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.humpath.2025.105911_bib7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.gendis.2023.06.017","article-title":"IGF2BPs as novel m6A readers: diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironment","volume":"11","author":"Duan","year":"2023","journal-title":"Genes Dis"},{"issue":"3","key":"10.1016\/j.humpath.2025.105911_bib8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/cncr.35048","article-title":"Association of the m6 A reader IGF2BP3 with tumor progression and brain-specific metastasis in breast cancer","volume":"130","author":"Li","year":"2024","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.105911_bib9","first-page":"3","article-title":"IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: a tissue microarray study on 8,877 human cancers and normal tissues","volume":"39","author":"Burdelski","year":"2018","journal-title":"Oncol Rep"},{"key":"10.1016\/j.humpath.2025.105911_bib10","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.2147\/OTT.S128810","article-title":"Prognostic value of high IMP3 expression in solid tumors: a meta-analysis","volume":"10","author":"Chen","year":"2017","journal-title":"OncoTargets Ther"},{"issue":"3","key":"10.1016\/j.humpath.2025.105911_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.humpath.2010.06.003","article-title":"The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology","volume":"42","author":"Findeis-Hosey","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2025.105911_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.humpath.2017.03.013","article-title":"IMP3 expression in biopsy specimens as a diagnostic biomarker for colorectal cancer","volume":"64","author":"Wei","year":"2017","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105911_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12885-022-10353-5","article-title":"IMP3 overexpression predicts poor prognosis and correlates with immune infiltration in bladder cancer","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.humpath.2025.105911_bib14","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3390\/cancers14092319","article-title":"Prognostic value of IGF2 mRNA-Binding protein 3 (IGF2BP3) intratumoral expression in melanoma patients at the time of diagnosis: comparative analysis of RT-qPCR versus immunohistochemistry","volume":"14","author":"S\u00e1nchez-Sendra","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.humpath.2025.105911_bib15","first-page":"2579","article-title":"Insulin-like growth factor-binding protein-3 in osteosarcomas and normal bone tissues","volume":"29","author":"Ressler","year":"2009","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.humpath.2025.105911_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10735-011-9370-2","article-title":"The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis","volume":"43","author":"Chen","year":"2012","journal-title":"J Mol Histol"},{"issue":"11","key":"10.1016\/j.humpath.2025.105911_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050621","article-title":"Up-regulation of Imp3 confers in vivo tumorigenicity on murine osteosarcoma cells","volume":"7","author":"Ueki","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.humpath.2025.105911_bib18","first-page":"2438","article-title":"Correlations of expressions of IMP3 and VEGF with stage of osteosarcoma, microvascular density and pulmonary metastasis","volume":"25","author":"Kong","year":"2020","journal-title":"J BUON"},{"issue":"4","key":"10.1016\/j.humpath.2025.105911_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.prp.2016.02.006","article-title":"Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma","volume":"212","author":"Shooshtarizadeh","year":"2016","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.humpath.2025.105911_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2024.100483","article-title":"IMP3, CDK4, MDM2 and \u03b2-catenin expression in enchondroma and central chondrosarcoma: diagnostic and prognostic utility","volume":"79","author":"Losada","year":"2024","journal-title":"Clinics"},{"issue":"7","key":"10.1016\/j.humpath.2025.105911_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s12094-015-1280-4","article-title":"Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis","volume":"17","author":"Zhang","year":"2015","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105911_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1620\/tjem.255.27","article-title":"The expression of insulin-like growth factor 2 messenger RNA-binding protein 3 in Langerhans cell histiocytosis and Langerhans cell sarcoma","volume":"255","author":"Yashige","year":"2021","journal-title":"Tohoku J Exp Med"},{"issue":"9","key":"10.1016\/j.humpath.2025.105911_bib23","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/s41417-023-00637-8","article-title":"Extracellular vesicle-associated IMP3 tunes ewing sarcoma cell migration and affects PI3K\/Akt pathway in neighboring cells","volume":"30","author":"Mancarella","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.humpath.2025.105911_bib24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3389\/fonc.2020.00994","article-title":"Insulin-like growth factor 2 mRNA-Binding protein 3 modulates aggressiveness of ewing sarcoma by regulating the CD164-CXCR4 axis","volume":"10","author":"Mancarella","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2025.105911_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.968884","article-title":"Polymorphic variants of IMP3 and SENCR have an impact on predisposition and\/or progression of ewing sarcoma","volume":"12","author":"Martinelli","year":"2022","journal-title":"Front Oncol"},{"issue":"15","key":"10.1016\/j.humpath.2025.105911_bib26","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1158\/1078-0432.CCR-17-2602","article-title":"Insulin-like growth factor 2 mRNA-Binding protein 3 is a novel post-transcriptional regulator of ewing sarcoma malignancy","volume":"24","author":"Mancarella","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.humpath.2025.105911_bib27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000001355","article-title":"FOS expression in osteoid osteoma and osteoblastoma: a valuable ancillary diagnostic tool","volume":"43","author":"Amary","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2025.105911_bib28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/BF01229533","article-title":"Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone","volume":"119","author":"Ueda","year":"1993","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.humpath.2025.105911_bib29","article-title":"CCN3 proteins as a diagnostic marker in osteosarcoma patients: a case control study","volume":"28","author":"Siddiqui","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10.1016\/j.humpath.2025.105911_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13018-016-0470-2","article-title":"Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"10.1016\/j.humpath.2025.105911_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13000-020-01051-6","article-title":"KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics","volume":"15","author":"Jiang","year":"2020","journal-title":"Diagn Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105911_bib32","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/PAS.0000000000001054","article-title":"Fluorescent in situ hybridization for TP53 in the diagnosis of pediatric osteogenic sarcoma","volume":"42","author":"Marrano","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105911_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/PAS.0000000000002214","article-title":"Insulin-like growth factor II mRNA-binding protein 3 is a highly sensitive marker for intravascular large B-cell lymphoma: immunohistochemical analysis of 152 pathology specimens from 88 patients","volume":"48","author":"Saka","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2025.105911_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3960\/jslrt.24025","article-title":"Insulin-like growth factor II mRNA binding protein 3 is highly expressed in primary diffuse large B-cell lymphoma of the CNS","volume":"64","author":"Odani","year":"2024","journal-title":"J Clin Exp Hematop"},{"issue":"10","key":"10.1016\/j.humpath.2025.105911_bib35","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.humpath.2013.04.011","article-title":"IMP3 as a supplemental diagnostic marker for hodgkin lymphoma","volume":"44","author":"Tang","year":"2013","journal-title":"Hum Pathol"},{"issue":"12","key":"10.1016\/j.humpath.2025.105911_bib36","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.humpath.2009.05.003","article-title":"IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue","volume":"40","author":"King","year":"2009","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2025.105911_bib37","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers13071505","article-title":"IGF2BP3 associates with proliferative phenotype and prognostic features in B-Cell acute lymphoblastic leukemia","volume":"13","author":"M\u00e4kinen","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725001984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725001984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:54:11Z","timestamp":1759859651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725001984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"alternative-id":["S0046817725001984"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105911","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world study on the expression and clinical application of IMP3 immunohistochemistry in bone tumors","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105911"}}